Coagulation factors IXa, XIa, and XIIa (FIXa, FXIa, FXIIa)

Coagulation factors IXa, XIa, and XIIa are activated serine proteases that constitute the intrinsic, or contact activation, pathway of the blood coagulation cascade. Factor XIIa initiates the process upon contact with negatively charged surfaces or polyanions, subsequently activating Factor XI to XIa, which then converts Factor IX to IXa (UniProt P00748, P03951, P00740). Factor IXa, acting within the tenase complex, is critical for the robust amplification of Factor X activation, leading to the burst of thrombin required for stable fibrin clot formation (StatPearls, Coagulation Cascade). While these factors are essential for pathological thrombosis, their role in physiological hemostasis is less dominant than the extrinsic pathway, making them attractive targets for 'safer' anticoagulants. Modern therapeutic strategies focus on inhibiting FXIa and FXIIa to decouple the prevention of thrombosis from the risk of clinical bleeding (PubMed, PMID: 33070333). Drugs targeting these factors, such as milvexian and garadacimab, are currently being evaluated for the prevention of stroke, venous thromboembolism, and the management of hereditary angioedema.

Other names

Intrinsic pathway serine proteasesActivated Christmas factor (IXa)Activated plasma thromboplastin antecedent (XIa)Activated Hageman factor (XIIa)Contact activation pathway factors

Inhibition of the enzymatic activity of activated serine proteases within the intrinsic coagulation pathway to prevent the sequential activation of downstream factors, ultimately reducing thrombin generation and fibrin formation.